Creating Value For Our Shareholders

Why Invest in Bayer

Report Highlights

q3-2022-ogimage

Quarterly Statement Third Quarter 2022

Investment Case

Event Highlights

finger tipping smartphone

February 28, 2023

Investor Conference Call

FY/Q4 2022 Results

Hands_with_smartphone

November 8, 2022

Investor Conference Call

Q3 2022 Results

CH Webinar_Teaser

September 15, 2022

Consumer Health Investor Webinar September 2022

PH_Asundexian_Header

August 29, 2022

Asundexian Investor Webinar August 2022

Girl using a drone with the sunset in the background

August 11, 2022

Crop Science Field Technology Showcase

Hands_with_smartphone

Investor Conference Call

Q2 2022 Results

enhancing-transparency

Enhancing Transparency: Bayer’s UN Global Compact adherence Webinar

Investor Conference Call

Q1 2022 Results

VIEW ALL EVENTS

News from Bayer

February 08, 2023

Bill Anderson to become CEO of Bayer AG

February 06, 2023

Not intended for U.S. and UK Media

Bayer submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU

February 02, 2023

Bayer and Kimitec join forces to bring the next generation of Biologicals to millions of growers worldwide

Sustainability & Governance

Our Commitment to Sustainability

Discover More Investor Resources

Returning Value to Shareowners

Detailed Insight into Debt & Fixed Income

Business man pointing on rising graph

Discover Our Interactive Stock Charts

CORPORATE GOVERNANCE

Managing and Supervising an Enterprise

CONTACT IR TEAM

Get In Touch With Us

USES AND SAFETY RECORD

Let’s Talk About Glyphosate

Learn About The Litigation

Glyphosate Litigation Facts

Subscribe To Our Latest Investor News